Overview
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
Status:
Completed
Completed
Trial end date:
2003-02-01
2003-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tabletPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Warner ChilcottTreatments:
Mesalamine
Criteria
Inclusion Criteria:- confirmed diagnosis of ulcerative colitis
Exclusion Criteria:
- a history of allergy or hypersensitivity to salicylates or aminosalicylates;
- a history of extensive small bowel resection